GTC Biotherapeutics (fka GTCB)

[DewDiligence]

For biogenerics, to a greater extent than for branded biopharmaceuticals, squeezing every possible basis point out of the COGS line will be consequential. That’s what makes GTC an excellent fit for the FoB arena in spite of the improvements that have been realized and will continue to be realized in cell-culture yields.